Apolipoproteins, the Lipid Hypothesis, and Ischemic Heart Disease

  • Pietro Avogaro
Conference paper
Part of the NATO ASI Series book series (NSSA, volume 84)


The development of atherosclerosis in man is complex and polifactorial process. Because elevated plasma levels of lipids and abnormal lipoprotein patterns have been identified as relevant risk factors for coronary atherosclerosis, major areas of scientific investigation have included the study of lipid (cholesterol, triglycerides, and phospholipids) and lipoprotein disorders. In recent years, lipoproteins have been classified according to their behavior in density-adjusted ultracentrifugation. Elevated plasma cholesterol and low density lipoproteins (LDL) are positively correlated with prevalence of coronary artery disease (Barr, Russ, and Eden, 1951; Kannel et al., 1961, 1971). Very low density lipoproteins (VLDL) and triglycerides once considered an independent risk factor (Böttiger and Carlson, 1980), are no longer thought to be valuable prognostic or discriminating factor (Heyden et al., 1980). In some groups of patients, the intermediate density lipoproteins (IDL) are significantly higher in atherosclerotic patients (Avogaro et al., 1979). An inverse relationship between coronary heart disease and high density lipoprotein (HDL) cholesterol has great statistical strength (Miller and Miller, 197S; Castelli et al., 1977). The suspicion exists that HDL2 or the ratio HDL2/HDL3 might be a more powerful predictor of protection from heart disease than is total HDL (Anderson et al., 1978). Some investigators, however, have recorded lower levels of both HDL2 and HDL3 in new cases of ischemic heart disease (IHD) (Gofman, Young, and Tandy, 1966) and in survivors of myocardial infarction (Avogaro et al., 1979).


High Density Lipoprotein Ischemic Heart Disease Intermediate Density Lipoprotein Lecithin Cholesterol Acyl Transferase Tangier Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahrens, E. H., Jr. Diet and heart disease shaping public perceptions when proof is lacking. Arteriosclerosis 2 (1982) 85–86.PubMedCrossRefGoogle Scholar
  2. Alaupovic, P. The role of apolipoproteins in lipid transport process. Research 12 (1982) 3–21.Google Scholar
  3. Alaupovic, P. Apolipoproteins and lipoproteins. Arteriosclerosis 13 (1971) 141–146.CrossRefGoogle Scholar
  4. Albers, J. J. et al. Quantitation of apolipoprotein A-I of human plasma high density lipoproteins. Metabolism 25 (1976) 633–644.PubMedCrossRefGoogle Scholar
  5. Anderson, D. W., Nichols, A. V., Pan, S. S., and Lindgren, F. T. High density lipoproteins distribution. Resolution and determination of three major components in a Normal Population sample. Arteriosclerosis 29 (1978) 161–179.CrossRefGoogle Scholar
  6. Assmann, G. Tangier disease and the possible role of high density lipoproteins in atherosclerosis. Atherosclerosis Review 6 (1979) 1–27.Google Scholar
  7. Avogaro, P., Bittolo-Bon, B., Cazzolato, G., Belussi, F., and Pontoglio, E. Apoproteins A and latent atherogenic dyslipoproteinemia. In J. L. De Gennes (ed.) Latent Dyslipoproteinaemias and atherosclerosis. New York: Raven Press, 1984. Pp. 147–155.Google Scholar
  8. Avogaro, P., Bittolo-Bon, G., Cazzolato, G., and Quinci, G. B. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet 1 (1979) 901–903.PubMedCrossRefGoogle Scholar
  9. Avogaro, P.. Cazzolato, G., Bittolo Bon, G., and Belussi, F. Levels and chemical composition of HDL2, HDL3 and other major lipoprotein classes in survivors of myocardial infarction. Artery 5 (1979) 495–508.Google Scholar
  10. Avogaro, P. et al. Lipoproteins derangement in human atherosclerosis. In Noseda, G., Fragiacomo, C., Fumagalli, R., Paoletti, R. (eds.) Lipoproteins and Coronary Atherosclerosis. Amsterdam: Elsevier Biomedical Press, 1982.Google Scholar
  11. Avogaro, P. et al. Plasma levels of apolipoprotein A-I and apolipoprotein B in human atherosclerosis. Artery 4 (1978) 385–394.Google Scholar
  12. Barr, D. P., Russ, E. M., and Eder, H. A. Protein-lipid relationship in human plasma II. In atherosclerosis and related conditions. Amererican Journal of Medicine 11 (1951) 480–484.CrossRefGoogle Scholar
  13. Berg, K., Borresen, A. L., and Dahlen, G. Serum high-density lipoprotein and atherosclerotic heart disease. Lancet 1 (1976) 499–501.PubMedCrossRefGoogle Scholar
  14. Böttiger, L. E. and Carlson, L. A. Risk factors for ischaemic vascular death for men in the Stockholm Prospective Study. Arteriosclerosis 36 (1980) 389–408.CrossRefGoogle Scholar
  15. Bradby, G. V. H., Valente, A. J., and Walton, K. W. Serum high-density lipoproteins in peripheral vascular disease. Lancet 2 (1978) 1271–1274.PubMedCrossRefGoogle Scholar
  16. Carlson, L. A. Fish eye disease: A new familial condition with massive corneal opacities and dyslipoproteinaemia. European Journal of Clinical Investigation 12 (1982) 41–53.PubMedCrossRefGoogle Scholar
  17. Castelli, W. P. et al. HDL cholesterol and other lipids in coronary heart disease. The Cooperative Lipoprotein Phenotyping Study. Circulation 55 (1977) 767–772.PubMedGoogle Scholar
  18. Curry, M. D., Alaupovic, P., and Suenram, C. A. Determination of apolipoprotein A and its constitutive A-I and A-II polypeptides by separate electroimmunoassays. Clinical Chemistry 22 (1976) 315–322.PubMedGoogle Scholar
  19. Franceschini, G. et al. Increased apoprotein B in very low density lipoproteins of patients with peripheral vascular disease. Arteriosclerosis 2 (1982) 74–80.PubMedCrossRefGoogle Scholar
  20. Franceschini, G. et al. A-I Milano apoprotein: Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in a Italian family. Journal of Clinical Investigation 66 (1980) 892–900.PubMedCrossRefGoogle Scholar
  21. Gidez, L. I., Swaney, J. B., and Murnane, S. Analysis of rat serum apolipoproteins by isoelectricfocusing. I. Studies on the middle molecular weight subunits of HDL and VLDL. Journal of Lipid Research 18 (1976) 69–76.Google Scholar
  22. Glomset, J. A. Physiological role of lecithin cholesterol acyl transferase. American Journal of Clinical Nutrition 23 (1970) 1129–1136.PubMedGoogle Scholar
  23. Gofman, J. W., Young, W., and Tandy, R. Ischaemic heart disease, atherosclerosis and longevity. Circulation 34 (1966) 679–697.PubMedGoogle Scholar
  24. Goldstein, J. L. et al. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. Journal of Clinical Investigation 52 (1973) 1533–1543.PubMedCrossRefGoogle Scholar
  25. Gustafson, A. et al. Identification of lipoprotein families in a variant of hyman plasma apolipoprotein A deficiency. Scandinavian Journal of Clinical and Laboratory Investigation 39 (1979) 377–387.PubMedCrossRefGoogle Scholar
  26. Havel, R. J. and Kane, J. P. Primary dysbetalipoproteinemia: Predominance of a specific apoprotein species in triglyceride rich lipoproteins. Proceedings of the National Academy of Sciences 70 (1973) 2015–2019.CrossRefGoogle Scholar
  27. Heyden, S., Heiss, G., Hames, C. G., and Burtel, A. G. Fasting triglycerides as predictors of total and CHD mortality in Evans County, Georgia. Journal of Chronic Disease 33 (1980) 272–282.Google Scholar
  28. Ishikawa, T. et al. The Tromso study: serum apolipoprotein A-I concentration in relation to future coronary heart disease. European Journal of Clinical Investigations (1978) 179–182.Google Scholar
  29. Kane, J. P. A rapid electrophoretic technique for identification of submit species of apoproteins in serum lipoproteins. Annals of Biochemistry 53 (1973) 350–364.CrossRefGoogle Scholar
  30. Kane, J. P., Hardman, D. A., and Paulus, H. E. Heterogeneity of apolipoprotein B: Isolation of a new species from human chylomicrons. Proceedings of the National Academy of Sciences 77 (1980) 2465–2469.CrossRefGoogle Scholar
  31. Kannel, W. B., Castelli, W. P.. Gordon, T., and MacNamara, P. M. Serum cholesterol, lipoproteins and the risk of coronary heart disease: The Framingham Study. Annals of Internal Medicine 74 (1971) 1–12.PubMedGoogle Scholar
  32. Kannel, W. B. et al. Factors of risk in the development of coronary heart disease. Six year follow-up experience. Annals of Internal Medicine 55 (1961) 33–50.PubMedGoogle Scholar
  33. Karlin, J. B., Juhn, D. J., Starr, J. L., and Rubenstein, A. H. Measurement of human high density lipoprotein apolipoprotein A-I in serum by radioimmunoassay. Journal of Lipid Research 17 (1976) 30–37.PubMedGoogle Scholar
  34. Kladetzky, R. G. et al. Lipoprotein and apoprotein values in coronary angiography patients. Artery 7 (1980) 191–205.PubMedGoogle Scholar
  35. Kwiterovich, P. et al. Familial hyperapobetalipoproteinemia in a Amish Kindred (Abstract). Arteriosclerosis 1 (1981) 87.Google Scholar
  36. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 (1970) 680–685.PubMedCrossRefGoogle Scholar
  37. Mann, G. V. Diet heart: End of an era. New England Journal of Medicine 297 (1977) 644–650.PubMedCrossRefGoogle Scholar
  38. B Maseri, A. Active and quiescent phases in coronarydisease. Role of varied and changing susceptibility to dynamic obstruction. Circulation 66 (suppl. II, IIB, C, D), 1982.Google Scholar
  39. Miller, C. J. and Miller, N. E. Plasma high-density lipoprotein concentration and development of ischaemic heart disease. Lancet 1 (1975) 16–19.PubMedCrossRefGoogle Scholar
  40. Norum, R. A. et al. Familial deficiency of apolipoproteins A-I and C-III precocious coronary-artery disease. New England Journal of Medicine 306 (1982) 1513–1519.PubMedCrossRefGoogle Scholar
  41. Outcherlony, O. Antigen-antibody reactions in gels. VI. Types of reactions in coordinated systems of diffusion. Acta Path. Microbiology of Scand. 32 (1953) 231–240.CrossRefGoogle Scholar
  42. Riesen, W., Mordasini, R., Salzmann, C., and Gurtner, H. P. Apoproteins in angiographically documented coronary heart disease. In Noseda, C., Fragiacomo, C., Fumagalli, R., and Paoletti, R. (eds.) Apoproteins in angiographically documented coronary heart disease. Amsterdam: Elsevier Biomedical Press, 1982.Google Scholar
  43. Schaefer, E. J., Eisenberg, S., and Levy, R. I. Lipoprotein apoprotein metabolism. Journal of Lipid Research 19 (1978) 667–687.PubMedGoogle Scholar
  44. Schaefer, E. J., Heaton, H. H., Wetzel, M. G., and Brewer, B. J., Jr. Plasma apolipoprotein A-I absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 2 (1982) 16–26.PubMedCrossRefGoogle Scholar
  45. Schaefer, E. J., Zech, L. A., Schwartz, D. E., and Brewer, H. B., Jr. Coronary heart disease prevalence and clinical features in familial high density lipoprotein deficiency (Tangier disease). Annals of Internal Medicine 93 (1980) 261–266.PubMedGoogle Scholar
  46. Sniderman, A. D. et al. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Annals of Internal Medicine 97 (1982) 833–939.PubMedGoogle Scholar
  47. Sniderman, A. D. et al. Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in plasma low density (B) lipoproteins. Proceedings of the National Academy of Sciences 77 (1980) 604–608.CrossRefGoogle Scholar
  48. Thompson, G. R.,.Teng, B., and Sniderman, A. Metabolic conversion of “light” to “heavy” low density lipoproteins (LDL) in subjects with normal and increased plasma LDL-apoB levels (Abstract). Circulation 66 (suppl. II) (1982) 158.Google Scholar
  49. Utermann, G. Human apolipoprotein mutants. In Schettler, G., Gotto, A. M., Middlehoff, G., Habenicht, A. J. R., and Jurutka, K. R. (eds.) Arteriosclerosis VI. Berlin: Springer-Verlag, 1983.Google Scholar
  50. Utermann, G., Hees, M., and Steinmetz, A. Polymorphysm of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 269 (1977) 604–607.PubMedCrossRefGoogle Scholar
  51. Vega, G. L. et al. Normocholesterolemic tendon xanthomatosis with overproduction of apolipoprotein B. Metabolism 32 (1983) 118–125.PubMedCrossRefGoogle Scholar
  52. Vergani, C. and Bettale, G. Familial hypo-alpha-lipoproteinaemia. Clinical Chim. Acta 114 (1981) 45–52.CrossRefGoogle Scholar
  53. Zannis, V. 1. et al. Proposed nomenclature of apoE isoproteins, apoE genotypes and phenotypes. Journal of Lipid Research 23 (1982) 911–914.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • Pietro Avogaro

There are no affiliations available

Personalised recommendations